Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

February 17, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

December 31, 2025

Conditions
Primary Biliary Cholangitis
Interventions
DRUG

Fenofibrate 200mg

Fenofibrate 200mg/day

DRUG

Placebo

1 tablet/ day

DRUG

UDCA

UDCA 13-15mg/kg/day

Trial Locations (12)

Unknown

RECRUITING

Peking Union Medical College Hospital, Beijing

NOT_YET_RECRUITING

Sun Yat-sen Memorial Hospital, Guangzhou

RECRUITING

Henan Provincial People's Hospital, Zhengzhou

RECRUITING

Xiangya Hospital Central South University, Changsha

RECRUITING

Jiangsu Province Hospital, Nanjing

RECRUITING

The First Hospital of China Medical University, Shenyang

RECRUITING

Xijing Hospital, Xi'an

RECRUITING

Yan'an University Affiliated Hospital, Yan’an

RECRUITING

Sichuan Provincial People's Hospital, Chengdu

RECRUITING

Tianjin Third Central Hospital, Tianjin

RECRUITING

The Second Affiliated Hospital of Kunming Medical University, Kunming

RECRUITING

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors
lead

Xijing Hospital of Digestive Diseases

OTHER